A Review of Albumin Binding in CKD

American Journal of Kidney Diseases

Volumn 51, Issue 5, 2008, Pages 839-850

  Meijers, Björn K I ^a   Bammens, Bert ^a   Verbeke, Kristin ^a   Evenepoel, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Albumin; albumin binding; chronic kidney disease; protein binding; review

Indexed keywords

ALBUMIN; CARRIER PROTEIN; LIGAND; SCAVENGER;

ADSORPTION; BINDING AFFINITY; BINDING SITE; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOALBUMINEMIA; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; PERITONEAL DIALYSIS; PROTEIN BINDING; REVIEW; SOLUTE;

ALBUMINS; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; LIGANDS; PROTEIN BINDING;

EID: 43049103117     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.12.035     Document Type: Review

References (106)

1. Armstrong J.A. Urinalysis in Western culture: A brief history. Kidney Int 71 (2006) 384-387
2. Dinneen S., and Gerstein H. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157 (1997) 1413-1418
3. Gerstein H.C., Mann J.F.E., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
4. Wachtell K., Ibsen H., Olsen M.H., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 139 (2003) 901-906
5. Hillege H.L., Fidler V., Diercks G.F.H., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
6. Obialo C.I., Okonofua E.C., Nzerue M.C., et al. Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney Int 56 (1999) 1058-1063
7. Jansen M.A.M., Termorshuizen F., Korevaar J.C., et al. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 68 (2005) 1199-1205
8. Termorshuizen F., Korevaar J.C., Dekker F., et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41 (2003) 1293-1302
9. Lowrie E.G., and Lew N.L. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 (1990) 458-482
10. Owen W.F., Lew N.L., Liu Y., et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329 (1993) 1001-1006
11. Breyer B., and Radcliff F. The adsorptive capacity of serum proteins in renal insufficiency. Austral J Exp Biol 32 (1954) 411-420
12. Himmelfarb J., Stenvinkel P., Ikizler T.A., et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 (2002) 1524-1538
13. Cohen M.P. Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch Biochem Biophys 419 (2003) 25-30
14. Thornalley P.J., Argirova M., Ahmed N., et al. Mass spectrometric monitoring of albumin in uremia. Kidney Int 58 (2000) 2228-2234
15. Dengler T., Robertz-Vaupel G., and Dengler H. Albumin binding in uraemia: Quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 43 (1992) 491-499
16. Kirsten R., Nelson K., Kirsten D., et al. Clinical pharmacokinetics of vasodilatators. Part I. Clin Pharmacokinet 34 (1998) 457-482
17. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 13 suppl 1 (2000) S18-S24
18. Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol 54 (1984) 17-29
19. Frishman W.H., and Alwarshetty M. β-Adrenergic blockers in systemic hypertension. Pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 41 (2002) 505-516
20. Vaughan C.J., and Gotto Jr. A.M. Update on statins: 2003. Circulation 110 (2004) 886-892
21. Davies N.M., and Skjodt N.A. Choosing the right anti-inflammatory drug for the right patient: A pharmacokinetic approach. Clin Pharmacokinet 38 (2000) 377-392
22. Musteata F.M., Pawliszyn J., Qian M.G., et al. Determination of drug plasma protein binding by solid phase microextraction. J Pharm Sci 95 (2006) 1712-1722
23. Ufer M. Comparative pharmacokinetics of vitamin K antagonists. Clin Pharmacokinet 44 (2005) 1227-1246
24. Rey E., Tréluyer J.-M., and Pons G. Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes. Clin Pharmacokinet 36 (1999) 409-424
25. Mahalati K., and Kahan B. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40 (2001) 573-585
26. Wallemacq P., and Verbeeck R.K. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40 (2001) 283-295
27. Akhlaghi F., and Trull A.K. Distribution of cyclosporin in organ transplant patients. Clin Pharmacokinet 41 (2002) 615-637
28. Nowak I., and Shaw L.M. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics. Clin Chem 41 (1995) 1011-1017
29. Sakai T., Takadate A., and Otagiri M. Characterisation of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 18 (1995) 1755-1761
30. Mabuchi H., Nakahashi H., Hamajima T., et al. The effect of renal transplantation on a major endogenous ligand retained in uremic serum. Am J Kidney Dis 13 (1989) 49-54
31. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63 (2003) 1934-1943
32. de Loor H., Bammens B., Evenepoel P., et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 51 (2005) 1535-1538
33. Bammens B., Evenepoel P., Keuleers H., et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69 (2006) 1081-1087
34. Martinez A.W., Recht N.S., Hostetter T.H., et al. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 16 (2005) 3430-3436
35. Meijers B.K.I., Loor Hd., Verbeke K., et al. p-Cresol for better or worse: But what are we measuring?. Kidney Int 70 (2006) 232
36. Niwa T., Nomura T., Sugiyama S., et al. The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 62 (1997) S23-S28
37. Sengupta S., Chen H., Togawa T., et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 276 (2001) 30111-30117
38. Peters T. All About Albumin (1996), Academic, London, UK
39. Arnadottir M., Hultberg B., Wahlberg J., et al. Serum total homocysteine concentration before and after renal transplantation. Kidney Int 54 (1998) 1380-1384
40. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Low dialysance of asymmetric dimethylarginine (ADMA)-In vivo and in vitro evidence of significant protein binding. Clin Nephrol 62 (2005) 295-300
41. Huang B., Dass C., and Kim H. Probing conformational changes of human serum albumin due to unsaturated fatty acid binding by chemical cross-linking and mass spectrometry. Biochem J 387 (2005) 695-702
42. Fasano M., Curry S., Terreno E., et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57 (2005) 787-796
43. Nakajou K., Watanabe H., Kragh-Hansen U., et al. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta General Subjects 1623 (2003) 88-97
44. Gulyassy P.F., and Depner T.A. Impaired binding of drugs and endogenous ligands in renal diseases. Am J Kidney Dis 2 (1983) 578-601
45. Odell G. The dissociation of bilirubin from albumin and its clinical implications. J Paediatr 55 (1959) 268-279
46. Sudlow G., Birkett D., and Wade D. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 11 (1975) 824-832
47. Chan T. Potential dangers from topical preparations containing methyl salicylate. Hum Exp Toxicol 15 (2006) 747-750
48. Biddle D.A., Wells A., and Dasgupta A. Unexpected suppression of free phenytoin concentration by salicylate in uremic sera due to the presence of inhibitors: MALDI mass spectrometric determination of molecular weight range of inhibitors. Life Sci 66 (1999) 143-151
49. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 40 (2002) 986-993
50. Masaki O. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 20 (2005) 309-320
51. Don B.R., and Kaysen G. Serum albumin: Relationship to inflammation and nutrition. Semin Dial 17 (2004) 432-437
52. Kaysen G.A. Albumin turnover in renal disease. Miner Electrolyte Metab 24 (1998) 55-63
53. Prinsen B.H.C.M., Rabelink T.J., Beutler J.J., et al. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int 64 (2003) 1495-1504
54. Pedrini L.A., Cozzi G., Faranna P., et al. Transmembrane pressure modulation in high-volume mixed hemodiafiltration to optimize efficiency and minimize protein loss. Kidney Int 69 (2006) 573-579
55. Kaysen G.A., Dubin J.A., Muller H.G., et al. Relationships among inflammation, nutrition, and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 61 (2002) 2240-2249
56. Kaysen G.A. Serum albumin concentration in dialysis patients: Why does it remain resistant to therapy?. Kidney Int Suppl 87 (2003) S92-S98
57. Stenvinkel P., Heimburger O., Paultre F., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 (1999) 1899-1911
58. Kalantar-Zadeh K., Ikizler T.A., Block G., et al. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 42 (2003) 864-881
59. Kaysen G., Greene T., Daugirdas J., et al. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 42 (2003) 1200-1211
60. Anraku M., Yamasaki K., Maruyama T., et al. Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res 18 (2001) 632-639
61. Mera K., Anraku M., Kitamura K., et al. Oxidation and carboxy methyl lysine-modification of albumin: Possible involvement in the progression of oxidative stress in hemodialysis patients. Hypertens Res 28 (2005) 973-980
62. Schalkwijk C.G., Ligtvoet N., Twaalfhoven H., et al. Amadori albumin in type 1 diabetic patients: Correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 48 (1999) 2446-2453
63. Berg T.J., Bangstad H.-J., Torjesen P.A., et al. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 46 (1997) 661-665
64. Jaisson S., Larreta-Garde V., Bellon G., et al. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 26 (2007) 190-196
65. Ivanov A.I., Korolenko E.A., Korolik E.V., et al. Chronic liver and renal diseases differently affect structure of human serum albumin. Arch Biochem Biophys 408 (2002) 69-77
66. Movilli E., Zani R., Carli O., et al. Correction of metabolic acidosis increases serum albumin concentrations and decreases kinetically evaluated protein intake in haemodialysis patients: A prospective study. Nephrol Dial Transplant 13 (1998) 1719-1722
67. Tsutsumi Y., Maruyama T., Takadate A., et al. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron 85 (2000) 60-64
68. Mabuchi H., and Nakahashi H. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia. Clin Chim Acta 167 (1987) 89-96
69. Vasson M., Baguet J., Roch Arveiller M., et al. Serum and urinary alpha-1 acid glycoprotein in chronic renal failure. Nephron 65 (1993) 299-303
70. Vanholder R., Van Landschoot N., De Smet R., et al. Drug protein binding in chronic renal failure: Evaluation of nine drugs. Kidney Int 33 (1988) 996-1004
71. Janku I. Physiological modelling of renal drug clearance. Eur J Clin Pharmacol 44 (1993) 513-519
72. Van Aubel R.A.M.H., Masereeuw R., and Russel F.G.M. Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 279 (2000) F216-F232
73. Jonker J.W., and Schinkel A.H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308 (2004) 2-9
74. Sun H., Frassetto L., and Benet L.Z. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109 (2006) 1-11
75. Evenepoel P., Bammens B., Nevens F., et al. The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. Liver Transpl 11 (2005) 853-854
76. Bammens B., Evenepoel P., Verbeke K., et al. Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. Am J Kidney Dis 44 (2004) 278-285
77. Meyer T.W., Leeper E.C., Bartlett D.W., et al. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol 15 (2004) 1927-1935
78. Meyer T.W., Walther J., Pagtalunan M.E., et al. The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int 68 (2005) 867-877
79. Bammens B., Evenepoel P., Verbeke K., et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64 (2003) 2238-2243
80. Evenepoel P., Bammens B., Verbeke K., et al. Superior dialytic clearance of β2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 70 (2006) 794-799
81. Bammens B., Evenepoel P., Verbeke K., et al. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 46 (2005) 512-519
82. Botella J., Ghezzi P.M., and Sanz-Moreno C. Adsorption in hemodialysis. Kidney Int Suppl 76 (2000) S60-S65
83. Gelfand M.C., and Winchester J.F. Hemoperfusion results in uremia. Clin Nephrol 11 (1979) 107-110
84. Rommes J., Sangster B., Berrens L., et al. Biocompatibility of hemoperfusion. Arch Toxicol 58 (1986) 187-195
85. Chang T.M.S. Assessment of clinical trials of charcoal hemoperfusion in uremic patients. Clin Nephrol 11 (1979) 111-119
86. Winchester J. Dialysis and hemoperfusion in poisoning. Adv Ren Replace Ther 9 (2002) 26-30
87. Pupim L.B., Caglar K., Hakim R.M., et al. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int 66 (2004) 2054-2060
88. Benet L., and Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71 (2002) 115-121
89. Weber L.T., Shipkova M., Armstrong V.W., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on mycophenolate mofetil therapy. J Am Soc Nephrol 13 (2002) 759-768
90. Gelder T.V., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145-154
91. Dasgupta A., and Abu-Alfa A. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds. Am J Clin Pathol 98 (1992) 19-25
92. Baily D.N., and Briggs J.R. The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit 26 (2004) 40-43
93. Dasgupta A., and Emerson L. Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: Lack of interaction in uremic sera due to the presence of endogenous factors. Ther Drug Monit 18 (1996) 654-659
94. Dasgupta A., Jacques M., and Malhotra D. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: Role of free fatty acids and uremic compounds. Am J Nephrol 16 (1996) 327-333
95. Saran R., Canaud B., Depner T.A., et al. Dose of dialysis: Key lessons from major observational studies and clinical trials. Am J Kidney Dis 44 (2004) 47-53
96. Lesaffer G., De Smet R., Lameire N., et al. Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 15 (2000) 50-57
97. Schepers E., Meert N., Glorieux G., et al. p-Cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22 (2007) 592-596
98. Cerini C., Dou L., Anfosso F., et al. p-Cresol, an uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 92 (2004) 140-150
99. Boure T., and Vanholder R. Biochemical and clinical evidence for uremic toxicity. Artif Organs 28 (2004) 248-253
100. Dou L., Bertrand E., Cerini C., et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65 (2004) 442-451
101. Motojima M., Hosokawa A., Yamato H., et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 63 (2003) 1671-1680
102. Jankowski V., Tolle M., Vanholder R., et al. Uridine adenosine tetraphosphate: A novel endothelium-derived vasoconstrictive factor. Nat Med 11 (2005) 223-227
103. Meyer T.W., Peattie J.W., Miller J.D., et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 18 (2007) 868-874
104. Mitzner S.R., Stange J., Klammt S., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 6 (2000) 277-286
105. Falkenhagen D., Strobl W., Vogt G., et al. Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances. Artif Organs 23 (1999) 81-86
106. Meijers B.K.I., Verhamme P., Nevens F., et al. Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant 7 (2007) 2195-2199